

Pharmacogenetics of Asthma Treatment (PHAT)

Scott T. Weiss, MD, Brigham and Women's Hospital

Augusto A. Litonjua, MD, Brigham and Women's Hospital
Kelán G. Tantsira, MD, Brigham and Women's Hospital
Elliot Israel, MD, Brigham and Women's Hospital
Ross Lazarus, MPH, Brigham and Women's Hospital
Thomas J. Mariani, PhD, Brigham and Women's Hospital
Steve D. Shapiro, MD, Brigham and Women's Hospital
Michael E. Wechsler, MD, Brigham and Women's Hospital
Jin Song Xu, PhD, Brigham and Women's Hospital
Eugene R. Bleecker, MD, Wake Forest University
Gregory Hawkins, PhD, Wake Forest University
Deborah A. Meyers, PhD, Wake Forest University
Nan M. Laird, PhD, Harvard School of Public Health
Christoph Lange, PhD, Harvard School of Public Health
Dennis W. McGraw, MD, University of Cincinnati
Kersten M. Small, PhD, University of Cincinnati
Marco F. Ramoni, PhD, Children's Hospital
Stephen B. Liggett, MD, University of Maryland

Using genetics to predict responders to asthma therapy, based upon understanding of asthma pathways and clinically significant variation

Funded by NHLBI

Pharmacogenomics and Risk of Cardiovascular Disease (PARC)

Ronald M. Krauss, MD, Children's Hospital Oakland Research Institute

Deborah A. Nickerson, PhD, University of Washington
Jerome I. Rotter, MD, Cedars-Sinai Medical Center
Xiuqing Guo, PhD, Cedars-Sinai Medical Center
Kent D. Taylor, PhD, Cedars-Sinai Medical Center
Dai Wang, PhD, Cedars-Sinai Medical Center
Paul T. Williams, PhD, Cedars-Sinai Medical Center
Daniel I. Chasman, MD, Brigham and Women's Hospital
Paul M. Ridker, PhD, Brigham and Women's Hospital
Nader R. Gherbranious, PhD, Marshfield Clinic
Catherine A. McCarty, PhD, Marshfield Clinic
Russell A. Wilkie, MD, PhD, Marshfield Clinic
Patricia J. Blanche, BS, Children's Hosp. Oakland Res. Inst.
Lara Mangravite, PhD, Children's Hosp. Oakland Res. Inst.
Mark J. Rieder, PhD, University of Washington
Joshua D. Smith, BS, University of Washington

Defining genetic contributions to differences among individuals in their responses to statin drugs and cardiovascular disease risk

Funded by NHLBI

Amish Pharmacogenomics of Antiplatelet Intervention Study (PAPI)

Alan R. Shuldiner, MD, University of Maryland

Stuart T. Haines, PharmD, University of Maryland
Braxton D. Mitchell, Jr., PhD, University of Maryland
Jeffrey R. O'Connell, PhD, University of Maryland
Toni I. Pollin, PhD, University of Maryland
Nauder Faraday, MD, Johns Hopkins University
William R. Herzog, MD, Johns Hopkins University
Wendy S. Post, MD, Johns Hopkins University

Understanding genetic determinants of responses that vary among people taking anti-platelet agents used to treat and prevent cardiovascular disease

Funded by NIGMS

PharmGKB: Catalyzing Research in Pharmacogenetics

Russ B. Altman, MD, PhD, Stanford University

Teri E. Klein, PhD, Stanford University
Tina M. Boussard, PhD, Stanford University
Michelle W. Carrillo, PhD, Stanford University
Mei Gong, MS, Stanford University
Winston Gor, MS, Stanford University
Mark Kiuchi, MBA, Stanford University
Feng Liu, MS, Stanford University
Andrew MacBride, BA, Stanford University
Caroline F. Thorn, PhD, Stanford University
TC Truong, BS, Stanford University
Mark Woon, BSE, Stanford University
Tina Zhou, MSE, MSP, Stanford University

Designing a knowledge base to link phenotypes to genotypes in pharmacogenetics and pharmacogenomics, to be used as a tool to enable future research efforts

Funded by NIGMS, NHLBI, NHGRI, and NLM

A goal of the PGRN and PharmGKB is to aid all researchers in understanding how genes vary among individuals, and how that affects drug safety and efficacy. The network hopes to set standards for future research studies, and make scientific recommendations that will ultimately impact the clinical use of drugs.



Pharmacogenetics - Research Network -

National Institutes of Health

U.S. Department of Health & Human Services

The NIH Pharmacogenetics Research Network (PGRN) is a nationwide collaboration of researchers studying the contribution of genetics to predicting responses to a wide variety of medicines. The overall aims of the groups are to discover important drug pathways, to identify sequence variants in relevant genes, and to establish biological relationships to clinical drug responses. Since its inception in 2000, scientists have studied genes and medications given for a range of diseases, including asthma, cancer, heart disease, and depression.

www.nigms.nih.gov/pharmacogenetics

PharmGKB

The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) is an integrated knowledge base for pharmacogenetics linking phenotypes and genotypes. It is available for the entire scientific community to make deposits and to use the data.

- A web-based format for pharmacogenetics knowledge
- Curated, linked genotypes and phenotypes
- Genomic, molecular and cellular, and clinical datasets
- Annotated, interactive, consensus drug pathways
- Automated methods for identifying relationships
- Community-based literature submissions
- Access to the entire research community

www.pharmgkb.org

Research Groups

Pharmacogenetics of Membrane Transporters (PMT)

Kathleen M. Giacomini, PhD, University of California, San Francisco

Deanna L. Kroetz, PhD, University of California, San Francisco
Leslie Z. Benet, PhD, University of California, San Francisco
Claire M. Brett, MD, University of California, San Francisco
Esteban G. Burchard, MD, University of California, San Francisco
Richard M. Castro, MD, University of California, San Francisco
Robert H. Edwards, MD, University of California, San Francisco
Thomas E. Ferrin, PhD, University of California, San Francisco
Charles E. Glatt, MD, PhD, University of California, Los Angeles
Pui-Yan Kwok, MD, PhD, University of California, San Francisco
Emil T. Lin, PhD, University of California, San Francisco
Victor I. Reus, MD, University of California, San Francisco
Neil J. Risch, PhD, University of California, San Francisco
Andrej Sali, PhD, University of California, San Francisco
Mark R. Segal, PhD, University of California, San Francisco
John S. Witte, PhD, University of California, San Francisco
Charles P. Quesenberry, Jr., PhD, University of California, Berkeley
Jasper J. Rine, PhD, University of California, Berkeley
Catherine A. Schaefer, PhD, Kaiser Permanente
Richard M. Myers, PhD, Stanford University
Wolfgang Sadec, PhD, Ohio State University

Studying membrane transporter genes in ethnically diverse samples, determining cellular phenotypes, and correlating variants with the clinical response to antidepressants

Funded by NIGMS, NIMH, and NCI

Comprehensive Research on Expressed Alleles in Therapeutic Intervention (CREATE)

Howard L. McLeod, PharmD, Washington University

Michael A. Province, PhD, Washington University
Mark Watson, MD, PhD, Washington University
Sharon Marsh, PhD, Washington University
Rakesh Nagarajan, PhD, Washington University
Gary Stormo, PhD, Washington University
Alan Templeton, PhD, Washington University
Barbara Zehnbauser, PhD, Washington University
Pui-Yan Kwok, MD, PhD, University of California, San Francisco

Identifying pathways of anti-cancer drugs, taking novel approaches to pathway dissection, and functionally assessing variants

Funded by NIGMS and NCI

Pharmacogenomics of Arrhythmia Therapy (PAT)

Dan M. Roden, MD, Vanderbilt University

Nancy J. Brown, MD, Vanderbilt University
Dawood Darber, MD, PhD, Vanderbilt University
Brian S. Donahue, MD, PhD, Vanderbilt University
Alfred L. George, Jr., MD, Vanderbilt University
Dario A. Giuse, PhD, Vanderbilt University
Jonathan L. Haines, PhD, Vanderbilt University
Prince J. Kannankeril, MD, Vanderbilt University
Richard B. Kim, MD, PhD, Vanderbilt University
Peter J. Mohler, PhD, Vanderbilt University
Marylyn D. Ritchie, PhD, Vanderbilt University
C. Michael Stein, MD, Vanderbilt University
Janey Wang, MS, Vanderbilt University
Ping Yang, PhD, Vanderbilt University
Tao Yang, PhD, Vanderbilt University
Patrick T. Ellinor, MD, PhD, Massachusetts General Hospital
Calum A. MacRae, MD, PhD, Massachusetts General Hospital
Theodore R. Addai, MD, Meharry Medical College
Michael D. Floyd, MD, Meharry Medical College
David J. Milan, MD, Brigham and Women's Hospital

Examining genes that modulate cardiac rhythm, accruing patients with QT responses to therapy, and evaluating drug responses in atrial fibrillation

Funded by NHLBI

Consortium on Breast Cancer Pharmacogenomics (COBRA)

David A. Flockhart, MD, PhD, Indiana University

Daniel F. Hayes, MD, University of Michigan
Vered Stearns, MD, Johns Hopkins University
Janet S. Carpenter, RN, PhD, Indiana University
Zeruesenay Desta, PhD, Indiana University
Stephen D. Hall, PhD, Indiana University
Lang Li, PhD, Indiana University
Sean D. Mooney, PhD, Indiana University
Anne Nguyen, BS, Indiana University
Todd C. Skaar, PhD, Indiana University
Anna Maria Storniolo, MD, Indiana University
James M. Rae, PhD, University of Michigan
Nancy E. Davidson, MD, Johns Hopkins University
Steffi Oestereich, PhD, Baylor University

Describing normal functions of estrogen, and how genetic variation contributes to efficacy and toxicity of endocrine treatments for breast cancer

Funded by NIGMS, NIEHS, and ORWH

Pharmacogenomic Evaluation of the Antihypertensive Response (PEAR)

Julie A. Johnson, PharmD, University of Florida

Eric Boerwinkle, PhD, University of Texas, Houston
Stephen T. Turner, MD, Mayo Clinic
Rhonda Cooper-DeHoff, PharmD, University of Florida
R. Whit Curry, MD, University of Florida
Yan Gong, PhD, University of Florida
John G. Gums, PharmD, University of Florida
Laurence Kennedy, MD, University of Florida
Taimour Langee, PhD, University of Florida
Issam Zineh, PharmD, University of Florida
Kent R. Bailey, PhD, Mayo Clinic
Gary L. Schwartz, MD, Mayo Clinic
Evelyn Baranco, MD, Emory University
Arlene B. Chapman, MD, Emory University
Andrei Rodin, PhD, University of Texas, Houston

Identifying gene variants involved in responses to drugs commonly used for hypertension, a beta-blocker and a thiazide diuretic, to predict therapeutic and adverse responses

Funded by NIGMS

Pharmacogenetics of Nicotine Addiction and Treatment (PNAT)

Neal L. Benowitz, MD, University of California, San Francisco and Huijun Z. Ring, PhD, SRI International

Stanley P. Azen, PhD, University of Southern California
David V. Conti, PhD, University of Southern California
Daniel O. Stram, PhD, University of Southern California
Duncan C. Thomas, PhD, University of Southern California
Peter D Karp, PhD, SRI International
Christina N. Lessov, PhD, SRI International
Yannick Pouliot, PhD, SRI International
Gary E. Swan, PhD, SRI International
Delia A. Dempsey, MD, University of California, San Francisco
Peyton Jacob III, PhD, University of California, San Francisco
Jennifer B. McClure, PhD, Group Health Cooperative
Caryn E. Lerman, PhD, University of Pennsylvania
Stephen I. Rennard, MD, University of Nebraska
Rachel T. Tyndale, PhD, University of Toronto

Investigating the genetic basis of nicotine addiction and influences on responses to drug therapies used for smoking cessation

Funded by NIDA, NIGMS, and NCI

Pharmacogenetics of Anticancer Agents Research Group (PAAR)

Mark J. Ratain, MD, University of Chicago and Mary V. Relling, PharmD, St. Jude Children's Research Hospital

Judith A. Badner, MD, University of Chicago
Nancy J. Cox, PhD, University of Chicago
Soma Das, PhD, University of Chicago
Christopher K. Daugherty, MD, University of Chicago
Apurva A. Desai, MD, University of Chicago
Anna DiRienzo, PhD, University of Chicago
M. Eileen Dolan, PhD, University of Chicago
Federico Innocenti, MD, PhD, University of Chicago
Wanqing Liu, PhD, University of Chicago
Amittha Wickrema, PhD, University of Chicago
Xiaolin Wu, PhD, University of Chicago
William E. Evans, PharmD., St. Jude Children's Research Hospital
Cheng Cheng, PhD, St. Jude Children's Research Hospital
Wei Liu, PhD, St. Jude Children's Research Hospital
Clayton W. Naeve, PhD, St. Jude Children's Research Hospital
Geoffrey A. M. Neale, PhD, St. Jude Children's Research Hospital
Deqing Pei, MS, St. Jude Children's Research Hospital
Ching-Hon Pui, MD, St. Jude Children's Research Hospital
Erin G. Schuetz, PhD, St. Jude Children's Research Hospital
John D. Schuetz, PhD, St. Jude Children's Research Hospital
Wenjian Yang, PhD, St. Jude Children's Research Hospital
Stephen C. Strom, MD, University of Pittsburgh
Gary L. Rosner, ScD, MD Anderson Cancer Center
Christopher I. Amos, PhD, MD Anderson Cancer Center
Edwin H. Cook, PhD, University of Illinois at Chicago

Elucidating the impact of germ-line variants on the efficacy and adverse effects of anti-cancer drugs used to treat colorectal cancer and childhood leukemias

Funded by NIGMS and NCI

Pharmacogenetics of Phase II Drug Metabolizing Enzymes (PPII)

Richard M. Weinshilboum, MD, Mayo Clinic

Eric D. Wieben, PhD, Mayo Clinic
Alex A. Adjei, MD, Mayo Clinic
John L. Black, III, MD, Mayo Clinic
Christopher G. Chute, MD, DrPH, Mayo Clinic
Julie M. Cunningham, PhD, Mayo Clinic
James N. Ingle, MD, Mayo Clinic
Sundeeep Khosla, MD, Mayo Clinic
David A. Mrazek, MD, FRC, Mayo Clinic
Janet E. Olson, PhD, Mayo Clinic
V. Shane Pankratz, PhD, Mayo Clinic
Daniel J. Schaid, PhD, Mayo Clinic
Celine M. Vachon, PhD, Mayo Clinic
Liewei Wang, MD, PhD, Mayo Clinic
Aman Buzdar, MD, MD Anderson Cancer Center
Vivien C. Yee, PhD, Case Western Reserve

Discovering variants and identifying mechanisms involved in phase II conjugating enzymes controlling biotransformation of drugs, hormones, and neurotransmitters

Funded by NIGMS and NCI